Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/31/2008 First Published: 3/22/2007


1.		Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				Other				UHW-AML16 EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480

Last Modified: 1/14/2009 First Published: 9/25/2004


2.		Phase III Randomized Study of Tipifarnib as Maintenance Therapy in Patients With Acute Myeloid Leukemia in Second or Subsequent Complete Remission or in First Complete Remission

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				ECOG-E2902 E2902, NCT00093470

Last Modified: 11/5/2008 First Published: 6/2/2006


3.		Phase I/II Study of Sorafenib in Combination With Erlotinib Hydrochloride, Tipifarnib, or Temsirolimus in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NABTC-05-02 NCT00335764

Last Modified: 1/8/2009 First Published: 5/1/2007


4.		Phase I/II Study of Tipifarnib and Sequential Paclitaxel Followed By Dose-Dense Doxorubicin Hydrochloride, Cyclophosphamide, and Tipifarnib in Patients With Stage IIB-IIIC Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NYCC-06-12-487 7868, NCT00470301


5.		Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				02 TETE 02 NCT00209989

Last Modified: 1/14/2009 First Published: 1/20/2006


6.		Phase II Randomized Study of Sorafenib in Combination With Either Temsirolimus or Tipifarnib in Patients With Unresectable Stage IV Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				SWOG-S0438 S0438, NCT00281957


7.		Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other				HEMOS AML 0106 EudraCT 2007-000273-35, NCT00510939

Last Modified: 12/30/2008 First Published: 1/18/2008


8.		Phase II Randomized Study of Tipifarnib and Etoposide as Induction Therapy in Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia (Treatment Arm II Closed to Accrual as of November 2008)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				70 and over				NCI				JHOC-MD017 MD017, JHOC-J07109, 8077, NCT00602771


9.		Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCRR				NCRR-M01RR00096-1001 M01RR00096, NCT00006199

Last Modified: 7/22/2008 First Published: 10/21/2005


10.		Phase I Study of Tipifarnib and Sorafenib in Patients With Advanced Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MDA-2005-0363 7156, NCI-7156, NCT00244972

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute